FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297996746> ?p ?o ?g. }

• W4297996746 abstract "Head and neck squamous cell carcinoma (HNSCC) is a huge burden in India with the majority of patients presenting in advanced unresectable stages. Innovative, low-cost but efficacious regimens that can be easily administered in the outpatient setting are the need of the hour. We envisaged assessing whether a readily available triplet therapy of erlotinib + methotrexate + 5-fluorouracil (EMF) is efficacious in terms of extending life and maintaining the quality of life in such patients.This was a single-arm, phase II, investigator-initiated interventional study. Thirty-five platinum-resistant/refractory patients of HNSCC were treated with a combination of erlotinib 150 mg, methotrexate 40 mg/m2 (d1, d8) and 5-fluorouracil 500 mg/m2 (d1, d8) every 28 days till progression or unacceptable toxicities. The primary endpoint was overall response rates (ORRs) at 3 months; additional endpoints were disease control rate (DCR) at 3 months, overall survival (OS) and progression-free survival (PFS), safety and patient-reported quality of life.The ORR and DCR at 3 months were 45.7% and 68.5%, respectively. The PFS was 5 months (95% confidence interval (95% CI): 3.9-6 months) and the OS was 9 months (95% CI: 7.4-10.5 months). The 3- and 6-month PFS rates were 86% ± 6% and 45% ± 9%, respectively, while the OS rates at 3 and 6 months were 91% ± 5% and 68% ± 8%, respectively. Rash, mucositis and fatigue were common adverse events occurring in 23 (65%), 14 (40%) and 9 (25.7%), respectively. The most common grade 3 events seen were rash in 5 (14.2%) and diarrhoea in 2 (5.7%). Clinically significant improvement from baseline was seen in many domains of Quality of Life Core Questionnaire and Quality of Life Head and Neck Module.The triplet regimen of EMF is a feasible and safe therapeutic option in patients with platinum-resistant/refractory HNSCC. It has demonstrated favourable response rates and improvement in quality of life; however, a randomised phase III study would add more robust value (NCT: CTRI/2020/02/023378)." @default.
• W4297996746 created "2022-10-01" @default.
• W4297996746 creator A5018716048 @default.
• W4297996746 creator A5032771147 @default.
• W4297996746 creator A5041157710 @default.
• W4297996746 creator A5047576756 @default.
• W4297996746 creator A5050913926 @default.
• W4297996746 creator A5070087707 @default.
• W4297996746 creator A5078356185 @default.
• W4297996746 creator A5086134236 @default.
• W4297996746 date "2022-09-29" @default.
• W4297996746 modified "2023-09-26" @default.
• W4297996746 title "A single-arm feasibility phase II study of EMF (erlotinib + methotrexate + 5-fluorouracil) regimen in platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)" @default.
• W4297996746 cites W1931708823 @default.
• W4297996746 cites W1934543498 @default.
• W4297996746 cites W1947168884 @default.
• W4297996746 cites W1989789581 @default.
• W4297996746 cites W2002052785 @default.
• W4297996746 cites W2003333623 @default.
• W4297996746 cites W2029409133 @default.
• W4297996746 cites W2033433258 @default.
• W4297996746 cites W2036067444 @default.
• W4297996746 cites W2063561065 @default.
• W4297996746 cites W2077854325 @default.
• W4297996746 cites W2128307218 @default.
• W4297996746 cites W2154196284 @default.
• W4297996746 cites W2160759339 @default.
• W4297996746 cites W2346836372 @default.
• W4297996746 cites W2529484692 @default.
• W4297996746 cites W2895683271 @default.
• W4297996746 cites W2903493423 @default.
• W4297996746 cites W2928092840 @default.
• W4297996746 cites W2947869359 @default.
• W4297996746 cites W2974744173 @default.
• W4297996746 cites W3128646645 @default.
• W4297996746 cites W5287737 @default.
• W4297996746 doi "https://doi.org/10.3332/ecancer.2022.1451" @default.
• W4297996746 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36405947" @default.
• W4297996746 hasPublicationYear "2022" @default.
• W4297996746 type Work @default.
• W4297996746 citedByCount "1" @default.
• W4297996746 countsByYear W42979967462023 @default.
• W4297996746 crossrefType "journal-article" @default.
• W4297996746 hasAuthorship W4297996746A5018716048 @default.
• W4297996746 hasAuthorship W4297996746A5032771147 @default.
• W4297996746 hasAuthorship W4297996746A5041157710 @default.
• W4297996746 hasAuthorship W4297996746A5047576756 @default.
• W4297996746 hasAuthorship W4297996746A5050913926 @default.
• W4297996746 hasAuthorship W4297996746A5070087707 @default.
• W4297996746 hasAuthorship W4297996746A5078356185 @default.
• W4297996746 hasAuthorship W4297996746A5086134236 @default.
• W4297996746 hasBestOaLocation W42979967461 @default.
• W4297996746 hasConcept C121608353 @default.
• W4297996746 hasConcept C126322002 @default.
• W4297996746 hasConcept C141071460 @default.
• W4297996746 hasConcept C143998085 @default.
• W4297996746 hasConcept C159110408 @default.
• W4297996746 hasConcept C168563851 @default.
• W4297996746 hasConcept C197934379 @default.
• W4297996746 hasConcept C203092338 @default.
• W4297996746 hasConcept C2776530083 @default.
• W4297996746 hasConcept C2776694085 @default.
• W4297996746 hasConcept C2776833033 @default.
• W4297996746 hasConcept C2778087573 @default.
• W4297996746 hasConcept C2778496288 @default.
• W4297996746 hasConcept C2778570526 @default.
• W4297996746 hasConcept C2779438470 @default.
• W4297996746 hasConcept C2779951463 @default.
• W4297996746 hasConcept C2780456651 @default.
• W4297996746 hasConcept C2780739268 @default.
• W4297996746 hasConcept C2781413609 @default.
• W4297996746 hasConcept C31760486 @default.
• W4297996746 hasConcept C71924100 @default.
• W4297996746 hasConceptScore W4297996746C121608353 @default.
• W4297996746 hasConceptScore W4297996746C126322002 @default.
• W4297996746 hasConceptScore W4297996746C141071460 @default.
• W4297996746 hasConceptScore W4297996746C143998085 @default.
• W4297996746 hasConceptScore W4297996746C159110408 @default.
• W4297996746 hasConceptScore W4297996746C168563851 @default.
• W4297996746 hasConceptScore W4297996746C197934379 @default.
• W4297996746 hasConceptScore W4297996746C203092338 @default.
• W4297996746 hasConceptScore W4297996746C2776530083 @default.
• W4297996746 hasConceptScore W4297996746C2776694085 @default.
• W4297996746 hasConceptScore W4297996746C2776833033 @default.
• W4297996746 hasConceptScore W4297996746C2778087573 @default.
• W4297996746 hasConceptScore W4297996746C2778496288 @default.
• W4297996746 hasConceptScore W4297996746C2778570526 @default.
• W4297996746 hasConceptScore W4297996746C2779438470 @default.
• W4297996746 hasConceptScore W4297996746C2779951463 @default.
• W4297996746 hasConceptScore W4297996746C2780456651 @default.
• W4297996746 hasConceptScore W4297996746C2780739268 @default.
• W4297996746 hasConceptScore W4297996746C2781413609 @default.
• W4297996746 hasConceptScore W4297996746C31760486 @default.
• W4297996746 hasConceptScore W4297996746C71924100 @default.
• W4297996746 hasLocation W42979967461 @default.
• W4297996746 hasLocation W42979967462 @default.
• W4297996746 hasLocation W42979967463 @default.
• W4297996746 hasOpenAccess W4297996746 @default.
• W4297996746 hasPrimaryLocation W42979967461 @default.
• W4297996746 hasRelatedWork W1993795346 @default.

• next